Boltwood Capital Management Sells 70 Shares of Danaher Co. (NYSE:DHR)

Boltwood Capital Management lowered its position in Danaher Co. (NYSE:DHRFree Report) by 1.6% during the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 4,430 shares of the conglomerate’s stock after selling 70 shares during the quarter. Boltwood Capital Management’s holdings in Danaher were worth $1,106,000 at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. Wellington Management Group LLP grew its position in Danaher by 12.0% in the fourth quarter. Wellington Management Group LLP now owns 27,928,442 shares of the conglomerate’s stock worth $6,460,966,000 after acquiring an additional 2,998,161 shares in the last quarter. Price T Rowe Associates Inc. MD grew its position in Danaher by 10.7% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 16,757,558 shares of the conglomerate’s stock worth $3,876,694,000 after acquiring an additional 1,619,586 shares in the last quarter. Capital International Investors grew its position in Danaher by 9.1% in the fourth quarter. Capital International Investors now owns 15,956,519 shares of the conglomerate’s stock worth $3,691,735,000 after acquiring an additional 1,334,781 shares in the last quarter. Northern Trust Corp grew its position in Danaher by 1.7% in the third quarter. Northern Trust Corp now owns 8,100,722 shares of the conglomerate’s stock worth $2,009,789,000 after acquiring an additional 134,905 shares in the last quarter. Finally, Norges Bank purchased a new position in Danaher in the fourth quarter worth $1,752,382,000. Institutional investors own 79.05% of the company’s stock.

Danaher Stock Up 1.3 %

Shares of DHR traded up $3.38 on Wednesday, hitting $257.51. 3,162,250 shares of the stock traded hands, compared to its average volume of 3,006,935. The company has a market capitalization of $190.74 billion, a PE ratio of 43.63, a P/E/G ratio of 3.89 and a beta of 0.85. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.51 and a current ratio of 1.85. The business has a 50 day simple moving average of $253.83 and a 200 day simple moving average of $244.91. Danaher Co. has a one year low of $182.09 and a one year high of $269.11.

Danaher (NYSE:DHRGet Free Report) last issued its earnings results on Tuesday, April 23rd. The conglomerate reported $1.92 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.72 by $0.20. Danaher had a net margin of 16.78% and a return on equity of 11.43%. The company had revenue of $5.80 billion for the quarter, compared to analysts’ expectations of $5.62 billion. During the same quarter last year, the company posted $2.36 earnings per share. The firm’s quarterly revenue was down 2.6% on a year-over-year basis. As a group, equities analysts forecast that Danaher Co. will post 7.63 earnings per share for the current fiscal year.

Danaher Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, July 26th. Stockholders of record on Friday, June 28th will be paid a dividend of $0.27 per share. This represents a $1.08 annualized dividend and a dividend yield of 0.42%. The ex-dividend date is Friday, June 28th. Danaher’s dividend payout ratio is presently 18.31%.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on DHR. Robert W. Baird upped their price target on shares of Danaher from $259.00 to $271.00 and gave the company an “outperform” rating in a research report on Wednesday, April 24th. StockNews.com upgraded shares of Danaher from a “hold” rating to a “buy” rating in a research report on Monday. TD Cowen upped their price target on shares of Danaher from $280.00 to $290.00 and gave the company a “buy” rating in a research report on Wednesday, April 24th. HSBC upgraded shares of Danaher from a “hold” rating to a “buy” rating and increased their target price for the stock from $250.00 to $280.00 in a report on Wednesday, April 17th. Finally, Citigroup increased their target price on shares of Danaher from $280.00 to $290.00 and gave the stock a “buy” rating in a report on Wednesday, April 24th. Five investment analysts have rated the stock with a hold rating and eleven have issued a buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $269.29.

View Our Latest Report on DHR

Insider Transactions at Danaher

In other news, CEO Rainer Blair sold 47,175 shares of Danaher stock in a transaction on Wednesday, April 24th. The shares were sold at an average price of $249.22, for a total transaction of $11,756,953.50. Following the transaction, the chief executive officer now owns 115,995 shares in the company, valued at approximately $28,908,273.90. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In other news, CEO Rainer Blair sold 47,175 shares of the firm’s stock in a transaction on Wednesday, April 24th. The shares were sold at an average price of $249.22, for a total transaction of $11,756,953.50. Following the sale, the chief executive officer now directly owns 115,995 shares in the company, valued at approximately $28,908,273.90. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Alan G. Spoon sold 708 shares of the firm’s stock in a transaction on Thursday, May 2nd. The shares were sold at an average price of $243.58, for a total transaction of $172,454.64. Following the sale, the director now owns 116,202 shares in the company, valued at $28,304,483.16. The disclosure for this sale can be found here. Insiders have sold 148,783 shares of company stock worth $37,536,717 in the last 90 days. 10.90% of the stock is currently owned by insiders.

Danaher Company Profile

(Free Report)

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.

Featured Articles

Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Co. (NYSE:DHRFree Report).

Institutional Ownership by Quarter for Danaher (NYSE:DHR)

Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.